Big Bucks
April 26, 2007 on 10:00 pm | In Uncategorized | Comments Off For years big drugmakers ignored rare diseases. Now Novartis aims to reap billions of dollars in sales by focusing on them.Doctor Voices Dendreon Doubts
April 26, 2007 on 10:00 am | In Uncategorized | Comments Off A second oncologist, Maha Hussain of the University of Michigan, writes a letter to the FDA arguing the prostate drug is not ready for prime time.Cancer Drugs A Key In MedImmune Purchase
April 23, 2007 on 1:36 pm | In Uncategorized | Comments Off Keep an eye on the anti-cancer medicines AstraZeneca is getting with its $15 billion deal.The Danger In Dendreon
April 20, 2007 on 2:00 pm | In Uncategorized | Comments Off Why the prostate cancer-fighting biotech is an extremely risky investment.Dosing For Dollars
April 17, 2007 on 2:00 pm | In Uncategorized | Comments Off Profit drives higher dosing of Amgen's anti-anemia drug Epogen, study finds.
Powered by WordPress with Pool theme design by Borja Fernandez.